NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: bevacizumab
Drug: vinorelbine tartrate
Other: laboratory biomarker analysis

First Posted Date: 2003-06-12

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00017394

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vitamin K and Bone Turnover in Postmenopausal Women

Phase 3

Completed

Conditions: Osteoporosis

First Posted Date: 2003-06-12

Last Posted Date: 2016-05-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 375

Registration Number: NCT00062595

Locations: 🇺🇸
University of Wisconsin Osteoporosis Clinical Research Prog., Madison, Wisconsin, United States

Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients

Phase 2

Completed

Conditions: Kidney Transplantation

First Posted Date: 2003-06-12

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 20

Registration Number: NCT00062712

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: estramustine phosphate sodium
Drug: docetaxel
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2003-06-10

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00016107

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: gefitinib
Other: pharmacological study
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2003-06-10

Last Posted Date: 2013-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00014170

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Undifferentiated Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
L1 Adult Acute Lymphoblastic Leukemia
L1 Childhood Acute Lymphoblastic Leukemia
L2 Adult Acute Lymphoblastic Leukemia
L2 Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia

Interventions: Drug: allopurinol
Drug: cyclophosphamide
Drug: daunorubicin hydrochloride
Drug: vincristine sulfate
Drug: dexamethasone
Drug: asparaginase
Biological: filgrastim
Drug: imatinib mesylate
Drug: methotrexate
Drug: cytarabine
Drug: trimethoprim-sulfamethoxazole
Drug: mercaptopurine
Drug: leucovorin calcium
Biological: alemtuzumab
Drug: acyclovir
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-06-06

Last Posted Date: 2022-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 302

Registration Number: NCT00061945

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

Phase 2

Completed

Conditions: Gastric Adenocarcinoma
Stage II Gastric Cancer
Stage III Gastric Cancer
Stage IV Gastric Cancer

Interventions: Drug: Cisplatin
Procedure: Computed Tomography
Radiation: Fludeoxyglucose F-18
Other: Fluorothymidine F-18
Drug: Irinotecan Hydrochloride
Procedure: Positron Emission Tomography
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2003-06-06

Last Posted Date: 2017-07-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00062374

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Promyelocytic Leukemia (M3)
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: romidepsin

First Posted Date: 2003-06-06

Last Posted Date: 2015-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00062075

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Recurrent Gastric Cancer
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Stage IIIC Gastric Cancer
Diffuse Adenocarcinoma of the Stomach
Stage IIIB Gastric Cancer
Stage IV Gastric Cancer